ABX 203

Drug Profile

ABX 203

Alternative Names: ABX-203; Anti-HBV therapeutic vaccine - Abivax/CIGB; Hepatitis B vaccine - CIGB; NASVAC

Latest Information Update: 25 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology; Wittycell
  • Developer Abivax; Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants; Natural killer cell receptor agonists; Natural killer T cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatitis B

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Dec 2016 Abivax completes a phase-II/III trial in Hepatitis B in New Zealand and Australia (NCT02249988)
  • 26 Feb 2015 Phase-II/III clinical trials in Hepatitis B in New Zealand (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top